home / stock / ptix / ptix short
Short Information | Protagenic Therapeutics Inc. (OTCMKTS:PTIX)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 7,305 |
Total Actual Volume | 17,373 |
Short Trends | |
---|---|
Cover Days | 6 |
Short Days | 11 |
No Change Days | 3 |
Averages | |
---|---|
Average Short Volume | 365 |
Average Short Percentage | 52.07% |
Is there a PTIX Short Squeeze or Breakout about to happen?
See the PTIX Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
04-26-2021 | $4.15 | $3.71 | $4.15 | $3.71 | 1,114 | 1,108 | 99.46% |
04-21-2021 | $4.9 | $4.9 | $4.9 | $4.9 | 551 | 500 | 90.74% |
04-19-2021 | $5.2 | $4.82 | $5.2 | $4.82 | 367 | 261 | 71.12% |
04-15-2021 | $6.25 | $5.2 | $6.25 | $5.2 | 2,396 | 1,331 | 55.55% |
04-13-2021 | $6.5 | $6.5 | $6.75 | $6.5 | 1,672 | 100 | 5.98% |
03-23-2021 | $6.05 | $6.25 | $6.25 | $6.05 | 200 | 100 | 50% |
03-22-2021 | $5.8 | $5.8 | $5.8 | $5.8 | 276 | 115 | 41.67% |
03-11-2021 | $5.7 | $5.7 | $5.7 | $5.7 | 120 | 117 | 97.5% |
03-08-2021 | $6.25 | $6.25 | $6.25 | $6.25 | 136 | 100 | 73.53% |
03-04-2021 | $6.51 | $6.51 | $6.51 | $6.51 | 310 | 15 | 4.84% |
02-26-2021 | $5.65 | $5.65 | $5.65 | $5.65 | 415 | 200 | 48.19% |
02-19-2021 | $6 | $5.5 | $6 | $5.5 | 749 | 90 | 12.02% |
02-18-2021 | $5.6 | $5.6 | $5.6 | $5.6 | 211 | 15 | 7.11% |
02-12-2021 | $4.16 | $4.15 | $4.16 | $4.15 | 405 | 235 | 58.02% |
01-28-2021 | $4.55 | $4.15 | $4.55 | $4.15 | 222 | 216 | 97.3% |
01-26-2021 | $4 | $4.165 | $7 | $3.8 | 5,270 | 1,973 | 37.44% |
01-13-2021 | $3 | $2.44 | $3 | $1.7 | 350 | 100 | 28.57% |
01-12-2021 | $2.15 | $2.15 | $2.15 | $2.15 | 344 | 279 | 81.1% |
06-09-2020 | $2 | $2 | $2 | $2 | 510 | 400 | 78.43% |
07-25-2018 | $2.00 | $1.25 | $2.00 | $1.25 | 1,755 | 50 | 2.85% |
News, Short Squeeze, Breakout and More Instantly...
Protagenic Therapeutics Inc. Company Name:
PTIX Stock Symbol:
OTCMKTS Market:
Chief Operating Officer to Present Key Advances at Peptide Therapeutics Summit NEW YORK, NY / ACCESSWIRE / April 17, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a pioneer in biopharmaceutical research, announced today that Dr. Andrew Slee, Chief Operating Officer, will present a tal...
Transitioned from Pre-Clinical to Clinical Stage company in FY 2023 Phase 1/2a trial, designed to assess both healthy volunteers and patients diagnosed with Treatment-Resistant Depression, PTSD or Generalized Anxiety Disorder, progressing through Phase 1 portion Plans to enroll final tw...
Next clinical progress update expected in April 2024 NEW YORK, NY / ACCESSWIRE / March 27, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a leader in biopharmaceutical innovation, advances its mission to develop cutting-edge treatments for stress-related neuropsychiatric disorders. The ...